Business
Notice of Investor Webinar
Notice of Investor Webinar.
About this update from Kromek Group Plc
[{"type":"text","content":"\n\n10 May 2023 \nKromek Group plc \n(\"Kromek\" or the \"Group\") \n \nNotice of Investor Webinar\n\nKromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that it will be hosting a webinar for investors at 18:00 on Monday 15 May 2023. \n \nThe presentation will be hosted by Arnab Basu, CEO, and Paul Farquhar, CFO, and will provide investors with an update on the business and the outlook for the coming year.\n \nThe call is open to all existing and potential shareholders. Interested parties can register to attend using the following link: https://forms.gle/zQLEYv7XjhJttsnE7. Participants are requested to submit questions in advance by 17:00 on 12 May 2023.\n \nNo new material financial information or update on current trading will be disclosed. \n \n \nFor further information, please contact: \n \n\n\n\nKromek Group plc \n\n\n\n\n\n\n\nArnab Basu, CEO \nPaul Farquhar, CFO \n \n\n\n+44 (0)1740 626 060\n\n\n\n\nfinnCap Ltd (Nominated Adviser and Broker) \n\n\n \n\n\n\n\nGeoff Nash/Seamus Fricker/George Dollemore - Corporate Finance \nTim Redfern/Charlotte Sutcliffe - ECM \n \n\n\n+44 (0)20 7220 0500 \n \n\n\n\n\nGracechurch Group (Financial PR) \n\n\n\n\n\n\n\nHarry Chathli/Claire Norbury \n \n\n\n+44 (0)20 4582 3500\n\n\n\n\n\n\n\n\n\n\n\nKromek Group plc \n \nKromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions. \n \nThe advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings. \n \nIn CBRN detection, the Group provides nuclear radiation de...